TransMedics Group, Inc. (TMDX) stock
TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/3029% below fair value
$91.38−0.62 (-0.67%)
Close on Nov 13, 2026Market cap $3.17BP/E 25.0Yield 0.00%
TransMedics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
TransMedics's EPS for the twelve months ending Sep 30, 2026 was $3.65, up 47.8% year over year. For fiscal 2025 it was $4.87, up 382.2% from the year before. The highest annual figure on record is $4.87 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.87 | +382.2% |
| FY2024 | Dec 31, 2024 | $1.01 | – |
| FY2023 | Dec 31, 2023 | -$0.77 | – |
| FY2022 | Dec 31, 2022 | -$1.23 | – |
| FY2021 | Dec 31, 2021 | -$1.60 | – |
| FY2020 | Dec 31, 2020 | -$1.16 | – |
| FY2019 | Dec 28, 2019 | -$2.36 | – |
| FY2018 | Dec 29, 2018 | -$17.48 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.46 | -30.3% |
| Q2 FY2026 | Jun 30, 2026 | $0.41 | -55.4% |
| Q1 FY2026 | Mar 31, 2026 | $0.20 | -71.4% |
| Q4 FY2025 | Dec 31, 2025 | $2.58 | +1257.9% |
| Q3 FY2025 | Sep 30, 2025 | $0.66 | +450.0% |
| Q2 FY2025 | Jun 30, 2025 | $0.92 | +162.9% |
| Q1 FY2025 | Mar 31, 2025 | $0.70 | +100.0% |
| Q4 FY2024 | Dec 31, 2024 | $0.19 | +58.3% |
| Q3 FY2024 | Sep 30, 2024 | $0.12 | – |
| Q2 FY2024 | Jun 30, 2024 | $0.35 | – |
| Q1 FY2024 | Mar 31, 2024 | $0.35 | – |
| Q4 FY2023 | Dec 31, 2023 | $0.12 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.78 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.03 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.08 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.21 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.25 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.41 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.38 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.46 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.47 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.39 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.29 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.23 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.19 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.36 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.42 | – |
| Q4 FY2019 | Dec 28, 2019 | -$0.43 | – |
| Q3 FY2019 | Sep 28, 2019 | -$0.39 | – |
| Q2 FY2019 | Jun 29, 2019 | -$0.70 | – |
| Q1 FY2019 | Mar 30, 2019 | -$4.86 | – |
| Q4 FY2018 | Dec 29, 2018 | -$5.48 | – |
| Q3 FY2018 | Sep 29, 2018 | -$3.73 | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.57 | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.61 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?